| Title | Image-Guided Percutaneous I-125 Seed Implantation as a Salvage Treatment for Recurrent Soft Tissue Sarcomas After Surgery and Radiotherapy |
| Authors | Li, Jinna Wang, Junjie Meng, Na Qu, Ang Yuan, Huishu Liu, Chen Ran, Weiqiang Jiang, Yuliang |
| Affiliation | Peking Univ, Hosp 3, Ctr Canc, Dept Radiat Oncol, Beijing 100191, Peoples R China. Peking Univ, Hosp 3, Dept Radiol, Beijing 100191, Peoples R China. Peking Univ, Hosp 3, Dept Ultrasound, Beijing 100191, Peoples R China. Peking Univ, Hosp 3, Ctr Canc, Dept Radiat Oncol, 49 Hua Yuan Beil Lu, Beijing 100191, Peoples R China. |
| Keywords | CT I-125 seed implantation radiotherapy recurrent soft tissue sarcoma surgery ultrasound outcome EXTERNAL-BEAM RADIOTHERAPY FUNCTION-SAVING RESECTION RADIATION-THERAPY WOUND COMPLICATIONS INTRAOPERATIVE BRACHYTHERAPY INTERSTITIAL BRACHYTHERAPY ADJUVANT BRACHYTHERAPY SURGICAL RESECTION RANDOMIZED-TRIAL LOCAL-CONTROL |
| Issue Date | 2011 |
| Publisher | cancer biotherapy and radiopharmaceuticals |
| Citation | CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS.2011,26,(1),113-120. |
| Abstract | The purpose of this study was to evaluate the safety and efficacy of percutaneous iodine-125 (I-125) seed implantation using computed tomography (CT) or ultrasound guidance in the treatment of recurrent soft tissue malignancies after surgery and radiotherapy. From February 2002 to September 2009, 18 patients with recurrent soft tissue sarcomas were treated under ultrasound or CT guidance. The actuarial median number of I-125 seeds implanted was 35 (range, 6-129), and the actuarial D90 of the implanted I-125 seeds ranged from 107.9 to 204.4 Gy (median, 147.1 Gy). The activity of the seeds ranged from 0.4 to 0.8 mCi (median, 0.7mCi). Follow-up times ranged from 4 to 78 months (median, 20 months). The median local control was 41 months (95% CI, 15.9-66.1 months). The 1-, 2-, 3-, 4-, and 5-year local controls were 78.8%, 78.8%, 78.8%, 26.3%, and 0%, respectively. The median survival was 32 months (95% CI, 16-48 months). The actuarial 1-, 2-, 3-, 4-, and 5-year survivals were 76.6%, 61.3%, 39.4%, 39.4%, and 39.4%, respectively. Seven (7) patients (38.9%) experienced recurrence after seed implantation. Six (6) patients (33.3%) died of distant metastases and 1 died of stroke. Two (2) patients developed ulceration, 1 case caused by recurrence and another by a reaction of the skin to radiation. Percutaneous I-125 seed implantation for recurrent soft tissue malignancies under CT or ultrasound guidance is safe and is associated with high efficacy and low morbidity. |
| URI | http://hdl.handle.net/20.500.11897/309532 |
| ISSN | 1084-9785 |
| DOI | 10.1089/cbr.2010.0847 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 第三医院 |
